Investment report on NMT Medical released

NewsGuard 100/100 Score announces an investment report featuring NMT Medical Inc. (Nasdaq:NMTI). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

NMT Medical Inc. (NMTI) is a medical technology company that designs, develops, manufactures and markets implant technologies that enables interventional cardiologists to treat structural heart disease, through catheter-based procedures. During the year ended December 31, 2009, the Company's revenues were derived from sales of its CardioSEAL, STARFlex and BioSTAR products primarily in the United States, Europe and Latin America. It also re-sells third party products for use with the CardioSEAL, STARFlex and BioSTAR implant devices, vascular sizing balloons and sheaths. BioSTAR is the Company's bioabsorbable patent foramen ovale (PFO) implant and the biological closure technology. Its customers include hospitals, clinics and other healthcare centers.

Message Board Search for NMTI:

In the report, the analyst notes:

"For the first quarter of 2010, NMTI reported a net loss of approximately $7.9 million, or $0.54 per share, compared with a net loss of approximately $3.8 million, or $0.29 per share, for the corresponding period in 2009. Cardiac septal repair implant sales in North America for the first quarter of 2010 were approximately $2.0 million compared with approximately $2.3 million in the first quarter of 2009. Implant sales outside of North America were approximately $1.0 million in the first quarter of 2010 compared with $1.2 million in the corresponding period of 2009.

 "NMTI recently announced that it has received preliminary results for CLOSURE I, its patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial in the United States. CLOSURE I is the first fully enrolled, randomized clinical trial to evaluate the effectiveness of PFO treatment in preventing recurrent strokes and TIAs. Analysis of the data for CLOSURE I commenced in April 2010."

To read the entire report visit:


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Azenta opens the doors to its new genomics laboratory in Oxford, UK